News
Aim to accelerate progress of lead candidate ISM-001 for peripheral ischaemia to clinic
IsomAb Ltd has announced two key appointments. Dr Shi Yin Foo joins the Board as a Non-Executive Director (NED), while Dr Gary Burgess is confirmed as Chief Medical Officer (CMO). Both bring extensive experience in the cardiovascular drug development field as IsomAb accelerates pre-clinical work for lead candidate ISM-001.
IsomAb Ltd, a UK-based biotechnology company developing developing isoform-specific, disease modifying antibody treatments for serious and life-threatening diseases, today announced it has entered into a strategic collaboration with Catalent, Inc.; the leader in enabling the development and supply of better treatments for patients worldwide.
NOTTINGHAM, UK – April 16th, 2024 – IsomAb Ltd, a UK-based biotechnology company developing isoform-specific disease modifying antibody treatments for serious and life-threatening diseases, today announced the appointment of Dr Anker Lundemose to its Board of Directors, as an independent non-executive Director. This follows the recent closing of a £7.5 million Seed funding in late February.
NOTTINGHAM, UK – Feb 20th 2024 – IsomAb Ltd, a UK-based biotechnology company, announced today the closing of a £7.5 million (approximately US$9.4 million) Seed financing round, led by Broadview Ventures, with further backing from existing investor, SCVC and participation from MEIF Proof of Concept & Early Stage Fund, which is managed by Mercia Ventures and part of the Midlands Engine Investment Fund (MEIF).